Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
The persistence of latently infected resting CD4+ T cells has been clearly demonstrated in human immunodeficiency virus (HIV)-infected individuals receiving effective antiviral therapy. However, estimates of the half-life of this viral reservoir have been quite divergent. We demonstrate clear evidence for decay of this HIV reservoir in patients who initiated antiviral therapy early in infection. The half-life of this latent viral reservoir was estimated to be 4.6 months. It is projected that it will take up to 7.7 years of continuous therapy to completely eliminate latently infected resting CD4+ T cells in infected individuals who initiate antiviral therapy early in HIV infection.
Chun
Tae-Wook
TW
Laboratory of Immunoregulation, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. twchun@nih.gov
Justement
J Shawn
JS
Moir
Susan
S
Hallahan
Claire W
CW
Maenza
Janine
J
Mullins
James I
JI
Collier
Ann C
AC
Corey
Lawrence
L
Fauci
Anthony S
AS
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology*; D015331:Cohort Studies; D006678:HIV / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008137:Longitudinal Studies; D013997:Time Factors; D019562:Viral Load; D017735:Virus Latency / Q000187:drug effects / Q000502:physiology*; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents